relation to the age of anticipated vaccination, by whether any disease falls outside the target population, and by the ability to formulate a vaccine effective against all strains/types causing disease. Factors influencing the estimate of the proportion of vaccine preventable illness are discussed in relevant sections of Appendixes D-1 through D-19.
Calculate vaccine preventable illness (VPI) values for each disease/vaccine combination. In this analysis, VPI values are calculated from TDBVs using the estimate of the proportion of the disease burden that is potentially preventable. A more exacting approach is to estimate for each disease in each age group/morbidity category combination, the number of cases, complications, sequelae, or deaths that could theoretically be prevented annually (in a steady state of vaccine use) and then use IME values to calculate VPI values in a manner similar to that for deriving TDBVs as described in Chapter 4.
Calculate the possible reduction in morbidity and mortality (PRMM) for each vaccine. These figures represent vaccine preventable illness values adjusted for the predicted efficacy of the vaccine. For
The National Academies of Sciences, Engineering, and Medicine
500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
"7. Calculation and Comparison of the Health Benefits and Differential Costs Associated with Candidate Vaccines."
New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries.
Washington, DC: The National Academies Press, 1986.
Please select a format: